Go Pro
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free LENZ Stock Alerts

LENZ Therapeutics (LENZ) Competitors

LENZ Therapeutics logo
$5.40 -0.19 (-3.47%)
As of 12:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

LENZ vs. EIKN, FDMT, DRUG, PRME, and DNA

Should you buy LENZ Therapeutics stock or one of its competitors? MarketBeat compares LENZ Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENZ Therapeutics include Eikon Therapeutics (EIKN), 4D Molecular Therapeutics (FDMT), Bright Minds Biosciences (DRUG), Prime Medicine (PRME), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

How does LENZ Therapeutics compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Eikon Therapeutics has higher earnings, but lower revenue than LENZ Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eikon TherapeuticsN/AN/AN/A-$2.46N/A
LENZ Therapeutics$20.99M8.07-$82.13M-$3.60N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eikon Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Eikon Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eikon TherapeuticsN/A N/A N/A
LENZ Therapeutics -519.30%-46.82%-43.32%

Eikon Therapeutics presently has a consensus price target of $25.20, suggesting a potential upside of 148.15%. LENZ Therapeutics has a consensus price target of $29.80, suggesting a potential upside of 451.34%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Eikon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, LENZ Therapeutics had 5 more articles in the media than Eikon Therapeutics. MarketBeat recorded 7 mentions for LENZ Therapeutics and 2 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.93 beat LENZ Therapeutics' score of 0.64 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eikon Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

LENZ Therapeutics beats Eikon Therapeutics on 7 of the 12 factors compared between the two stocks.

How does LENZ Therapeutics compare to 4D Molecular Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, LENZ Therapeutics had 5 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 7 mentions for LENZ Therapeutics and 2 mentions for 4D Molecular Therapeutics. LENZ Therapeutics' average media sentiment score of 0.64 beat 4D Molecular Therapeutics' score of 0.63 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
4D Molecular Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LENZ Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$20.99M8.07-$82.13M-$3.60N/A
4D Molecular Therapeutics$88.24M6.98-$140.11M-$2.57N/A

LENZ Therapeutics presently has a consensus target price of $29.80, indicating a potential upside of 451.34%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 153.72%. Given LENZ Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than 4D Molecular Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
4D Molecular Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

LENZ Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, indicating that its share price is 170% more volatile than the broader market.

4D Molecular Therapeutics has a net margin of -182.34% compared to LENZ Therapeutics' net margin of -519.30%. 4D Molecular Therapeutics' return on equity of -36.83% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-519.30% -46.82% -43.32%
4D Molecular Therapeutics -182.34%-36.83%-32.55%

Summary

4D Molecular Therapeutics beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Bright Minds Biosciences has higher earnings, but lower revenue than LENZ Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bright Minds BiosciencesN/AN/A-$8.74M-$2.44N/A
LENZ Therapeutics$20.99M8.07-$82.13M-$3.60N/A

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bright Minds Biosciences has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Bright Minds Biosciences' return on equity of -20.58% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bright Minds BiosciencesN/A -20.58% -20.25%
LENZ Therapeutics -519.30%-46.82%-43.32%

In the previous week, LENZ Therapeutics had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for LENZ Therapeutics and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.83 beat LENZ Therapeutics' score of 0.64 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bright Minds Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bright Minds Biosciences presently has a consensus price target of $143.83, indicating a potential upside of 94.05%. LENZ Therapeutics has a consensus price target of $29.80, indicating a potential upside of 451.34%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Bright Minds Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Minds Biosciences
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Bright Minds Biosciences has a beta of -5.34, meaning that its share price is 634% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Summary

Bright Minds Biosciences beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Prime Medicine and Prime Medicine both had 7 articles in the media. Prime Medicine's average media sentiment score of 0.81 beat LENZ Therapeutics' score of 0.64 indicating that Prime Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LENZ Therapeutics has a net margin of -519.30% compared to Prime Medicine's net margin of -4,917.55%. LENZ Therapeutics' return on equity of -46.82% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime Medicine-4,917.55% -188.82% -60.97%
LENZ Therapeutics -519.30%-46.82%-43.32%

Prime Medicine presently has a consensus price target of $7.53, indicating a potential upside of 111.26%. LENZ Therapeutics has a consensus price target of $29.80, indicating a potential upside of 451.34%. Given LENZ Therapeutics' higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Prime Medicine has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

LENZ Therapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.63M139.07-$201.14M-$1.23N/A
LENZ Therapeutics$20.99M8.07-$82.13M-$3.60N/A

Summary

Prime Medicine beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Ginkgo Bioworks?

LENZ Therapeutics (NASDAQ:LENZ) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

LENZ Therapeutics currently has a consensus target price of $29.80, indicating a potential upside of 451.34%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential downside of 7.00%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe LENZ Therapeutics is more favorable than Ginkgo Bioworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

LENZ Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$20.99M8.07-$82.13M-$3.60N/A
Ginkgo Bioworks$151.40M3.94-$312.76M-$5.36N/A

In the previous week, LENZ Therapeutics had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 7 mentions for LENZ Therapeutics and 1 mentions for Ginkgo Bioworks. LENZ Therapeutics' average media sentiment score of 0.64 beat Ginkgo Bioworks' score of -0.40 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ginkgo Bioworks
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ginkgo Bioworks has a net margin of -215.41% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-519.30% -46.82% -43.32%
Ginkgo Bioworks -215.41%-56.08%-26.06%

LENZ Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LENZ Therapeutics beats Ginkgo Bioworks on 10 of the 16 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LENZ vs. The Competition

Export
MetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$169.94M$3.65B$6.85B$12.50B
Dividend YieldN/A2.19%2.68%8.01%
P/E Ratio-1.5121.1327.2424.41
Price / Sales8.07218.06525.3596.46
Price / CashN/A61.9829.2449.38
Price / Book0.598.5610.986.35
Net Income-$82.13M$23.83M$3.58B$330.93M
7 Day Performance-3.48%-2.06%-1.43%-1.79%
1 Month Performance-20.16%7.51%4.01%-0.04%
1 Year Performance-84.42%53.79%28.83%20.91%

LENZ Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LENZ
LENZ Therapeutics
2.7488 of 5 stars		$5.40
-3.5%		$29.80
+452.3%		-83.9%$169.12M$20.99MN/A110
EIKN
Eikon Therapeutics
2.1321 of 5 stars		$13.05
+2.4%		$25.20
+93.1%		N/A$706.51MN/AN/A384
FDMT
4D Molecular Therapeutics
1.7606 of 5 stars		$13.30
+3.3%		$29.88
+124.6%		+187.6%$695.27M$88.24MN/A120
DRUG
Bright Minds Biosciences
2.3469 of 5 stars		$70.20
+1.5%		$143.83
+104.9%		+213.7%$683.19MN/AN/AN/A
PRME
Prime Medicine
3.1829 of 5 stars		$3.69
-0.8%		$7.53
+104.1%		N/A$666.49M$4.63MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 7/13/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Hidden on Tesla's filing: A $12 billion "super startup"
Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...
Banyan Hill Publishing | Sponsoredtc pixel